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In spite of a perceived shortage of evidence to support Burnett’s
immune surveillance theory for the majority of solid tumours (for
example, the relative absence of non-viral tumours in AIDS
patients) there is considerable interest in the hypothesis that the
immune system may be actively suppressed in patients with malig-
nant disease. Patients with solid tumours have been shown to have
reduced cell-mediated immunity as assessed by skin testing
(Medical Oncology Society, 1979; King et al, 1997). Furthermore,
it has been reported that the risk of tumour recurrence is increased
if this immune suppression is not reversed (Cole and Humphrey,
1985). A reduction in the number of peripheral blood T-lympho-
cytes and in the proportions of CD4 and CD8 T-lymphocytes in
patients with solid tumours (Tancini et al, 1990; Tsutsui et al,
1992) and a reduced CD4 lymphocyte count occur in patients with
advanced colorectal carcinoma when compared to normal controls
(Arista et al, 1994). Lymphocyte numbers and proportions may
give an indication of immune status but fail to give an absolute
measure of tumour-specific immune function, although the greater
reduction in lymphocyte numbers in patients with advanced
tumours, compared to patients with less advanced tumours,
suggests an associative role.
Cytokine production by stimulated monocytes/macrophages
during antigen presentation is an integral part of the immune
response and involves production of both pro-inflammatory
cytokines such as tumour necrosis factor-a (TNF-a) and inter-
feron-g (IFN-g) and immunosuppressive cytokines such as inter-
leukin-10 (IL-10). The aim of this study was to investigate the
effect of primary colorectal carcinoma on monocyte/macrophage
function, as represented by the production of TNF-a, IFN-g and
IL-10 in stimulated whole blood cultures, both prior to and
following surgical resection of the tumour.
MATERIALS AND METHODS
Heparinized venous blood was collected from 40 patients (26
male, 14 female) with primary colorectal cancer prior to treatment
and 31 similarly aged controls (14 male, 17 female). All patients
were informed of the study and gave written consent. The study
was approved by the local ethical committee. Serial blood samples
were obtained following surgical resection of the tumour, if
performed, and at outpatient visits during post-operative follow-
up. Clinical data regarding the patient and tumour histology were
recorded. In the majority of the patients, the white blood count and
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were either healthy or had benign, non-inflammatory conditions
and none were taking steroids or any form of immunosuppression.
Blood was diluted in RPMI-1640 medium (1:4) + glutamine 
(2 mM) and either stimulated with lipopolysaccharide (LPS; 1 mg
ml–1; Sigma, Escherichia coli serotype 0127:B8) by incubation in
24-well plates at 37°C/5% carbon dioxide for 24 h or left unstimu-
lated under the same conditions. Cell-free supernatants were
collected by microcentrifugation and stored in aliquots at –70°C
until analysis. Supernatants were assayed for TNF-a, IFN-g and
IL-10 by enzyme-linked immunosorbent assay (ELISA) using an
assay procedure and reagents (anti-cytokine capture monoclonal
antibody, biotinylated anti-cytokine detecting antibody and recom-
binant cytokine) provided by Pharmingen (Cambridge Bioscience,
UK). In each case the manufacturers’ instructions were followed
exactly.
Statistical analysis
Data are presented as mean ± standard deviation (s.d.) from the
mean. Statistical analyses were performed using Mann–Whitney
U-tests for unpaired two group non-parametric data and
Kruskal–Wallis tests for non-parametric data when comparing
more than two groups. Analysis of variance, followed by Student’s
t-test, were used to compare age. In all tests, significance was
accepted at P < 0.05.
RESULTS
No cytokine production was observed in unstimulated cultures and
all the results presented below represent the results from LPS-
stimulated cultures only.
Levels of TNF-a, IFN-g and IL-10 were measured in culture
supernatants derived from patients prior to treatment. Production
of TNF-a in patients with colorectal tumours (median, 11 269 pg
ml–1, Interquartile range [IQR] 12 598 pg ml–1, n = 37) was signif-
icantly reduced compared to that of the control patients (20 576 pg
ml–1, 11 637 pg ml–1, n = 31; P < 0.0001) (Figure 1A). Production 
of IFN-g in patients with colorectal tumours (median, 0.00 pg ml–1,
IQR 226 pg ml–1, n = 40) was also significantly reduced 
when compared to controls (1048 pg ml–1, 2428 pg ml–1, n = 31; 
P = 0.0051) (Figure 1B). There was no difference in the level of 
IL-10 between patients with colorectal tumours (O.D.450: median
0.406, IQR 0.204; n = 38) and controls (O.D.450: median 0.436,
IQR 0.048, n = 24; P = NS) (Figure 1C). There was no significant
difference in age between the patients with colorectal tumours
(70.5 years ± 11.4 years) and the control patients (66.2 years ±
10.5 years; P = NS). There was no difference between patients
with colorectal cancer and controls in white blood count (8.7 ´ 109
l–1 ± 3.1, n = 33 vs 7.6 ´ 109 l–1 ± 1.8, n = 26 respectively; P = NS),
lymphocyte count (1.62 ´ 109 l–1 ± 0.6, n = 33 vs 1.9 ´ 109 l–1 ±
0.74, n = 26 respectively; P = NS), or monocyte count (0.7 ´ 109 l–1
± 0.25, n = 33 vs 0.6 ´ 109 l–1 ± 0.27, n = 26 respectively; P = NS),
and there was no difference across Dukes’ stages.
LPS-induced production of TNF-a and IFN-g and IL-10 were
assayed in all patients who were at least 20 weeks post-surgery
(range 20–44 weeks) with the most recent sample used. Produc-
tion of TNF-a in patients with colorectal cancer had increased
compared to production prior to resection of the tumour (median
17 620 pg ml–1, IQR 7986 pg ml–1, n = 15) and was no longer
significantly less than the control patients (P = 0.28) (Figure 1A).
Production of IFN-g in the cancer patients (median 410 pg ml–1,
IQR 2696 pg ml–1, n = 11) was also increased compared to prior to
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Figure 1 (A) TNF-a levels in stimulated whole blood in patients with colorectal cancer, prior to, and post-surgical resection, versus controls. (B) IFN-g levels in
stimulated whole blood in patients with colorectal cancer, prior to, and post-surgical resection, versus controls. (C) IL-10 levels in stimulated whole blood in
patients with colorectal cancer, prior to, and post-surgical resection, versus controls. NS: not significantsurgery and was no longer significantly less than the control
patients (P = 0.76) (Figure 1B). The level of IL-10 was unchanged
(median 0.423, IQR 0.053, n = 16) and remained similar to the
control patients (Figure 1C).
Levels of TNF-a, IFN-g and IL-10 production prior to any treat-
ment were compared to the Dukes’ stage of the tumour. Due to the
limited number of Dukes’ A stage tumours, Dukes’ A and B
tumour stages were combined, analysed as a single group of
tumours with spread confined to the bowel wall and compared
with Dukes’ C tumours, with spread to lymph nodes, and with
controls. There was a significant reduction in TNF-a levels in the
cancer patients compared to controls (median 20 576 pg ml–1, IQR
11 637 pg ml–1, n = 31) and this reduction was greater in patients
with Dukes’ C stage tumours (median 6894 pg ml–1, IQR 15 687
pg ml–1, n = 19) than with those with Dukes’ A or B stage tumours
(median 11 808 pg ml–1, IQR 10 352 pg ml–1, n = 21; P = 0.0004)
(Figure 2A). There was a significant reduction in IFN-g levels in
the cancer patients compared to controls (median 1048 pg ml–1,
IQR 2428 pg ml–1, n = 31) and this reduction was greater in
patients with Dukes’ C stage tumours (median 0.00 pg ml–1, IQR
213 pg ml–1, n = 19) than with those with Dukes’ A or B stage
tumours (median 13.0 pg ml–1, IQR 247 pg ml–1, n = 21; P = 0.014)
(Figure 2B). There was no demonstrable difference in IL-10
production in the cancer patients compared to the controls (median
0.436, IQR 0.048, n = 24) in either Dukes’ stage A and B tumours
(median 0.406, IQR 0.191, n = 18) or Dukes’ stage C tumours
(median 0.422, IQR 0.255, n = 19; P = 0.922) and there was no
difference in IL-10 levels across the Dukes’ stages (Figure 2C).
DISCUSSION
The interaction between the host immune system and malignant
tumours is complex and has been the subject of much debate. Only
melanoma, renal cell carcinoma and perhaps prostate carcinoma
(Hrouda et al, 1997) have clearly been accepted as immunologi-
cally sensitive solid tumours; immunotherapies, such as treatment
with IFN-a, IL-2 and vaccination strategies have provided some
evidence of efficacy (Mittelman et al, 1990). However, a large
number of patients do not respond to these therapies and such
approaches are mostly not envisaged with other tumours. One of
the many ways that a solid tumour can evade an effective immune
response is to induce immunosuppressive cytokines, such as IL-
10, which inhibit antigen presenting function (and thus cell-medi-
ated immunity), via down-regulation of MHC class II expression.
Therefore, the measurement of cytokine production by stimulated
monocytes provides an insight into the ability of the immune
system to respond to external stimuli.
The hypothesis of tumour-mediated immune suppression, as
suggested by previous studies assessing cell-mediated immunity
by skin hypersensitivity (Medical Oncology Society, 1979; King et
al, 1997) is supported by our study. We have shown a highly
significant reduction in production of TNF-a and IFN-g by LPS-
stimulated whole blood cultures derived from patients with
colorectal cancer as compared to similarly aged controls. This
suppression of cytokine production appears to be selective since
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Figure 2 (A)TNF-a levels in stimulated whole blood in patients with
colorectal cancer, divided by tumour stage (Duke’s stage), versus controls.
(B) IFN-g levels in stimulated whole blood in patients with colorectal cancer,
divided by tumour stage (Duke’s stage), versus controls. (C) IL-10 levels in
stimulated whole blood in patients with colorectal cancer, divided by tumour
stage (Duke’s stage), versus controls. NS: not significantthe production of IL-10, a cytokine responsible for monocyte
deactivation, was not affected, and as there was no difference in
leucocyte count between cancer patients and controls, it suggests a
functional suppression rather than a reduction in leucocyte
numbers as has been demonstrated with advanced colorectal
tumours (Arista et al, 1994). Elsasser-Beile et al (1992) reported
similar results with a reduction in production of TNF-a and IFN-g
in patients with colorectal carcinoma and no change in leucocyte
count though this was only studied at a single time point and the
effect of resection was not assessed.
Interestingly, we have also shown that suppression of TNF-a
and IFN-g production appears to disappear following resection of
the tumour. Surgery is known to result in a transient immune
suppression which usually resolves after 6–9 days (Hammer et al,
1992). However, in this study samples were taken from patients
prior to surgery and (after tumour resection) at a time distant
(greater than 20 weeks) to allow immunosuppression from the
surgery itself to resolve. McMillan et al (1997) have previously
reported that impaired immunity, as measured by decreased
lymphocyte subset populations, is important in tumour recurrence
in colorectal cancer. However, at present the follow-up on the
patients in this study is too limited to assess whether this is also the
case for cytokine production. It is also interesting to note that
impaired monocyte/macrophage function is apparent in patients
with primary tumours and is not restricted to patients with
advanced or metastatic disease as has previously been shown
(Arista et al, 1994; King et al, 1997). Our data strongly suggest
that the degree of functional impairment increases with tumour
stage. This may be due to specific characteristics of the tumour
which results in an increased propensity for invasion.
TNF-a production may also be an indicator of the degree of
tumour cell lysis during antibody-dependent cell-mediated cyto-
toxicity as it is released by monocytes when cross-linked to
tumour cells by anti-tumour antibody (Pullyblank et al, 1991).
Furthermore, tumour-induced down-regulation of IFN-g produc-
tion may represent a mechanism of inhibiting tumour-specific
CTL. IFN-g has an important role in the regulation of tumour cell
lysis and has been shown to increase the sensitivity of colon carci-
noma cell lines to Fas-mediated apoptosis (Darcy et al, 1998),
possibly via the induction of caspase expression. IFN-g is also
crucial for the induction of IL-12 which is a powerful inducer of
Th-1 type immunity and an important cytokine in the generation of
anti-tumour immunity. Interestingly, a recent study by O’Hara et al
(1998) has demonstrated that the production of IL-12 is deficient
in patients with colorectal cancer.
There is now considerable evidence that colorectal cancer will
respond to immunological interventions. The use of IL-12, either
as a preoperative treatment or in metastatic colorectal cancer is
claimed to be associated with an improved survival (compared to
current best supportive care) (Barni et al, 1995; Brivio et al, 1996).
Reithmuller and colleagues reported that a monoclonal antibody
(17-1A) to a colorectal antigen resulted in an improved survival
for patients with Dukes’ stage C colon cancer when given post
resection (Reithmuller et al, 1994).
In conclusion, our study suggests the need for therapeutic strate-
gies for both early and metastatic colorectal cancer to include
immunotherapy in order to boost cell mediated immunity and
monocyte function. This may also be required to allow other
passive or active immunotherapies to be effective. Further studies
should include prospective monitoring of patients with poor
cytokine responses given standard treatments with or without cell-
mediated enhancement, such as IL-2 administration. If relatively
non-toxic immunotherapy can prolong the survival of patients
with Dukes’ C (and hence probably Dukes’ B) colorectal cancer it
may prevent the need for exposure to 5-fluorouracil, with its
associated side-effects, which remains the current standard
chemotherapy.
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